Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Trial of the European and American Osteosarcoma Study Group to Optimize Treatment Strategies for Resectable Osteosarcoma Based on Histological Response to Pre-operative Chemotherapy

Next Previous
X
Search
Trial Profile

A Randomized Trial of the European and American Osteosarcoma Study Group to Optimize Treatment Strategies for Resectable Osteosarcoma Based on Histological Response to Pre-operative Chemotherapy

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 14 Jun 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Peginterferon alfa-2b (Primary) ; Cisplatin; Doxorubicin; Etoposide; Ifosfamide; Methotrexate
  • Indications Osteosarcoma
  • Focus Therapeutic Use
  • Acronyms EURAMOS-1

    • Most Recent Events

    • 24 Jan 2019 Results evaluating Survival outcomes and prognosis with osteosarcoma published in the European Journal of Cancer
    • 25 Aug 2016 Primary endpoint has not been met. (Event-free survival), as per an article published in the Lancet Oncology.
    • 25 Aug 2016 Results published in the Lancet Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top